ABVC BioPharma, Inc. (ABVC)

US — Healthcare Sector
Peers: INDP  KTTA  BTTX  FBRX  EVLO  APTX  MGTA  ALRN  ARDS  AKTX  ADTX  ACST  RNXT  ANEB  SABS  MNPR  ELDN  NTRB  QNRX  LGVN  VRAX 

Automate Your Wheel Strategy on ABVC

With Tiblio's Option Bot, you can configure your own wheel strategy including ABVC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABVC
  • Rev/Share 0.034
  • Book/Share 0.5315
  • PB 3.7944
  • Debt/Equity 0.4016
  • CurrentRatio 0.22
  • ROIC -0.1825

 

  • MktCap 23264792.0
  • FreeCF/Share -0.1253
  • PFCF -12.4025
  • PE -11.3172
  • Debt/Assets 0.1459
  • DivYield 0
  • ROE -0.3113

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About ABVC BioPharma, Inc. (ABVC)

  • IPO Date 2004-11-10
  • Website https://www.abvcpharma.com
  • Industry Biotechnology
  • CEO Dr. Uttam Yashwant Patil Ph.D.
  • Employees 16
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.